---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-103706"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2024-09-27T23:59:59+00:00"
generated_at: "2026-05-31T01:15:56.054651+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Nasdaq notifies TransCode of shareholder approval violation; adds to delisting risk

## Summary
- Received new Nasdaq deficiency letter on Sep 23, 2024 for failing to obtain shareholder approval for a deeply discounted offering.
- Offering on July 22, 2024 of 10M shares at $0.30/share (62% discount to Minimum Price) represented 137% of pre-transaction shares.
- Nasdaq determined discount >50% precludes public offering treatment, so shareholder approval was required under Rule 5635(d).
- This deficiency is an additional basis for delisting, beyond prior Minimum Bid Price and Stockholders' Equity deficiencies.
- Panel hearing scheduled for Oct 1, 2024 will consider all deficiencies; no assurance of continued listing on Nasdaq.

## SEC filing metadata
- accession: 0001104659-24-103706
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2024-09-27T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465924103706/0001104659-24-103706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465924103706/tm2424982d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-103706
- JSON: https://secwatch.observer/filing/0001104659-24-103706.json
- Plain text: https://secwatch.observer/filing/0001104659-24-103706.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.